CN108771718A - For hypoglycemic mixture containing plant component and the preparation method and application thereof - Google Patents
For hypoglycemic mixture containing plant component and the preparation method and application thereof Download PDFInfo
- Publication number
- CN108771718A CN108771718A CN201810912913.9A CN201810912913A CN108771718A CN 108771718 A CN108771718 A CN 108771718A CN 201810912913 A CN201810912913 A CN 201810912913A CN 108771718 A CN108771718 A CN 108771718A
- Authority
- CN
- China
- Prior art keywords
- tea
- hypoglycemic
- containing plant
- mixture containing
- plant component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 230000002218 hypoglycaemic effect Effects 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 241001122767 Theaceae Species 0.000 claims abstract description 123
- 238000000605 extraction Methods 0.000 claims abstract description 49
- 210000004369 blood Anatomy 0.000 claims abstract description 32
- 239000008280 blood Substances 0.000 claims abstract description 32
- 241000196324 Embryophyta Species 0.000 claims abstract description 22
- 239000003595 mist Substances 0.000 claims abstract description 13
- 229930006000 Sucrose Natural products 0.000 claims abstract description 10
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 9
- 239000005720 sucrose Substances 0.000 claims abstract description 9
- 235000013305 food Nutrition 0.000 claims abstract description 6
- 239000000284 extract Substances 0.000 claims description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 18
- 229910001868 water Inorganic materials 0.000 claims description 18
- 239000000706 filtrate Substances 0.000 claims description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 10
- 239000002552 dosage form Substances 0.000 claims description 9
- 235000019441 ethanol Nutrition 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 239000000654 additive Substances 0.000 claims description 7
- 239000003963 antioxidant agent Substances 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 230000000996 additive effect Effects 0.000 claims description 6
- 230000003078 antioxidant effect Effects 0.000 claims description 6
- 235000006708 antioxidants Nutrition 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- GOCCREQJUBABAL-UHFFFAOYSA-N 2,2-dihydroxyacetic acid Chemical compound OC(O)C(O)=O GOCCREQJUBABAL-UHFFFAOYSA-N 0.000 claims description 5
- 235000009024 Ceanothus sanguineus Nutrition 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- 240000003553 Leptospermum scoparium Species 0.000 claims description 5
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- 230000002335 preservative effect Effects 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 4
- 235000010323 ascorbic acid Nutrition 0.000 claims description 4
- 239000011668 ascorbic acid Substances 0.000 claims description 4
- 229960005070 ascorbic acid Drugs 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 235000003599 food sweetener Nutrition 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000003765 sweetening agent Substances 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 239000003472 antidiabetic agent Substances 0.000 claims description 3
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 3
- 239000008116 calcium stearate Substances 0.000 claims description 3
- 235000013539 calcium stearate Nutrition 0.000 claims description 3
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 claims description 3
- 238000000874 microwave-assisted extraction Methods 0.000 claims description 2
- 238000002137 ultrasound extraction Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 2
- 238000005260 corrosion Methods 0.000 claims 1
- 239000008103 glucose Substances 0.000 abstract description 17
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 16
- 230000000291 postprandial effect Effects 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 11
- 241000700159 Rattus Species 0.000 abstract description 10
- 108010028144 alpha-Glucosidases Proteins 0.000 abstract description 10
- 201000001421 hyperglycemia Diseases 0.000 abstract description 10
- 102100024295 Maltase-glucoamylase Human genes 0.000 abstract description 9
- 108090000637 alpha-Amylases Proteins 0.000 abstract description 9
- -1 polyphenol compounds Chemical class 0.000 abstract description 9
- 102000004139 alpha-Amylases Human genes 0.000 abstract description 8
- 230000002829 reductive effect Effects 0.000 abstract description 6
- 239000004382 Amylase Substances 0.000 abstract description 5
- 235000019418 amylase Nutrition 0.000 abstract description 5
- 235000013824 polyphenols Nutrition 0.000 abstract description 5
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 238000000354 decomposition reaction Methods 0.000 abstract description 2
- 238000005265 energy consumption Methods 0.000 abstract description 2
- 210000000936 intestine Anatomy 0.000 abstract description 2
- 235000014347 soups Nutrition 0.000 abstract description 2
- 210000000813 small intestine Anatomy 0.000 description 22
- 238000010171 animal model Methods 0.000 description 11
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 10
- 206010012601 diabetes mellitus Diseases 0.000 description 10
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 9
- 229940024171 alpha-amylase Drugs 0.000 description 7
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 235000013339 cereals Nutrition 0.000 description 6
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 5
- 208000002249 Diabetes Complications Diseases 0.000 description 5
- 206010012655 Diabetic complications Diseases 0.000 description 5
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 5
- 229960001948 caffeine Drugs 0.000 description 5
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 5
- 229940030275 epigallocatechin gallate Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 5
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- 102000013142 Amylases Human genes 0.000 description 4
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 4
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 4
- 235000005487 catechin Nutrition 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 4
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 3
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 3
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- 108010065511 Amylases Proteins 0.000 description 3
- 229950001002 cianidanol Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 3
- 235000012734 epicatechin Nutrition 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XMOCLSLCDHWDHP-DOMZBBRYSA-N (-)-gallocatechin Chemical compound C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-DOMZBBRYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 230000008753 endothelial function Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 2
- 229940074391 gallic acid Drugs 0.000 description 2
- 235000004515 gallic acid Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000003736 gastrointestinal content Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 201000009104 prediabetes syndrome Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 229960004559 theobromine Drugs 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 229930013915 (+)-catechin Natural products 0.000 description 1
- 235000007219 (+)-catechin Nutrition 0.000 description 1
- 229930014124 (-)-epigallocatechin gallate Natural products 0.000 description 1
- 235000004911 (-)-epigallocatechin gallate Nutrition 0.000 description 1
- WMBWREPUVVBILR-NQIIRXRSSA-N (-)-gallocatechin gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-NQIIRXRSSA-N 0.000 description 1
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- 244000235603 Acacia catechu Species 0.000 description 1
- 235000006226 Areca catechu Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010054805 Macroangiopathy Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 240000003152 Rhus chinensis Species 0.000 description 1
- 235000014220 Rhus chinensis Nutrition 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 239000003392 amylase inhibitor Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- VFSWRBJYBQXUTE-UHFFFAOYSA-N epi-Gallocatechin 3-O-gallate Natural products Oc1ccc2C(=O)C(OC(=O)c3cc(O)c(O)c(O)c3)C(Oc2c1)c4cc(O)c(O)c(O)c4 VFSWRBJYBQXUTE-UHFFFAOYSA-N 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000013138 pruning Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Botany (AREA)
- Nutrition Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention is provided to hypoglycemic mixtures containing plant component and its preparation method and application.The mixture includes tea stalk/tea stem micro mist or tea stalk/tea stem extraction.Tea stalk/tea stem can effectively prevent and reduce postprandial hyperglycemia rich in a variety of polyphenol compounds, reduce blood glucose fluctuation in the daytime, effectively prevent, mitigate and treat the complication caused by postprandial hyperglycemia.Zoopery proves, the tea stalk/tea stem extraction can inhibit the activity of intestine in rats alpha-glucosidase and amylase, reduce the decomposition of food source soup compound, reduce absorption of the enteron aisle to sugar, the blood glucose level of sucrose feeding rat is reduced, and then has the function that reduce postprandial blood sugar and improves sugar tolerance.The preparation process of the mixture is simple, energy consumption is low, pollution-free.
Description
Technical field
The invention belongs to hypoglycemic plant extracts technical fields, and in particular to the extract of tea stalk/tea stem.
Background technology
It rises year by year with living-pattern preservation, the incidence of carbohydrate metabolism disturbance with the improvement of living standards, it is not only sugared
It urinates patient's quantity to increase sharply, and there are a large amount of pre-diabetics.Clinical research shows that postprandial blood sugar lasting for a long time is different
It is often the distinguishing feature of Chinese type 2 diabetes patient, while is also the pathology of pre-diabetic and impaired glucose tolerance patient
Feature.By taking the diabetes investigation result of District of Shanghai as an example, in diabetes and pre-diabetic, increased with postprandial blood sugar
Proportion of patients be up to 88%, the simple raised ratio of postprandial blood sugar is up to 49%, and the raised ratio of simple fasting blood-glucose is only
Account for 12%.Further, since racial difference, China's Healthy crowd 2 hours blood glucose amplification after taking in equivalent carbohydrate is shown
It writes higher than European healthy population, and carbohydrate proportion is larger in Chinese's dietary structure, payes attention to postprandial blood sugar as early as possible
Management helps to delay morbidity and the diabetic's disease progression of onset diabetes people at highest risk.
Diabetic complication is the main reason for reducing quality of life in patients with diabetes and lead to patient disabilities, death.About
There is 1/2 patient when making a definite diagnosis diabetes, have complication and exist, and complication is once occur, it is difficult to reverse.Therefore pre- as early as possible
It is significant to extend patients ' lives to improving life in patients for anti-and treatment diabetic complication.Epidemiological study shows,
Hyperglycemia is related to a variety of diabetic complications after postprandial or load.Quick raised postprandial blood sugar causes blood glucose fluctuation, causes
Microvascular endothelial function reduction, vascular reactivity increase, and lead to such as retinopathy microangiopathies.On the other hand, after the meal
The acute raising of blood glucose can inhibit the release of damaging Nitric oxide and the blood vessel dilatation of endothelium-dependent relaxation, increase soluble glutinous
Attached molecule is horizontal, activates thrombosis, promotes response to oxidative stress and damage endothelial function, eventually leads to macroangiopathy.It removes
Except this, postprandial hyperglycemia can also increase osmotic pressure, increase platelet reactivity, activation blood platelet, with postprandial hypercoagulative state phase
It closes.Therefore, actively control and management postprandial blood sugar are the key that diabetic complication preventions.
The hormone in vivo such as level of postprandial blood sugar and insulin are related, also related with the intake of carbohydrate group food.It forms sediment
The absorption of the carbohydrate such as powder, carbohydrate needs the effect of the amylase and alpha-glucosidase of small intestinal mucosa brush border.Starch
The glucose that enzyme and glucosidase inhibitor class drug pass through participation carbohydrate degradation in competitive antagonism intestinal villi
Glycosides enzyme delays the decomposition and digestion of complex carbohydrates and disaccharide, postpones and reduce the absorption of the glucose in small intestine epimere,
Postprandial blood sugar amplification is reduced, blood glucose fluctuation in the daytime is reduced, prevents the generation of diabetes, delay diabetes de-velopment, prevent and reduce
The appearance of complication.
Tea (Camellia sinensis (L.) O.Kuntze), Theaceae dungarunga or undershrub plant originate in me
State, the present whole world, which is more than 60 countries, cultivation.Tealeaves has long applicating history, in addition to being world hobby drink
One of the raw material of material or the traditional medicine in China.Modern research shows that tea extract have preferable hypoglycemic, lipid-loweringing,
Lose weight, is anti-oxidant, anti-inflammatory isoreactivity, tea extract has been widely used for making health food and functional food additives
Deng for diseases such as auxiliary treatment hyperlipemia, obesity, diabetes, bacterium infections.However, with most of identical activity at
Tea stalk/tea the stem divided is not yet adequately used for prevention hyperglycemia.Tea stem is the waste material for trimming tea tree, and crushing can add as animal feeding-stuff
Add agent；Waste material after tealeaves makes when tea stalk has certain health value.
In this specification, tea stalk/tea stem refers to tea stalk or tea stem.
Invention content
The present invention is provided to hypoglycemic mixtures containing plant component and the preparation method and application thereof, it is intended to solve tea
Stalk/tea stem is for the technical issues of preventing postprandial hyperglycemia.
One of technical solution of the present invention is a kind of micro- for hypoglycemic mixture containing plant component, including tea stalk/tea stem
Powder or tea stalk/tea stem extraction.Tea stalk/tea stem contains epigallocatechin gallate, epi-nutgall acid catechu
The polyphenol compounds such as element, L-Epicatechin gallate, epicatechin.
Further, further include antioxidant, preservative and sweetener, the antioxidant is sulphite or Vitamin C
The mixture of both acid or more, the preservative are the mixture of both dihydroxy acetic acid or methaform or more, the sweet tea
Taste agent is sucrose or the mixture of lactose or PEARLITOL 25C or more three.
Further, further include excipient and lubricant, the excipient is both starch or avicel cellulose or more
Mixture, the lubricant is magnesium stearate or the mixture of calcium stearate or talcum powder or more three.
Further, the dosage form of use is granule, tablet, capsule or pill.
Include tea stem micro mist or tea stalk/tea stem extraction provided by the present invention for hypoglycemic mixture containing plant component
Object, tea stalk/tea stem can effectively prevent and reduce postprandial hyperglycemia rich in a variety of polyphenol compounds, reduce blood glucose wave in the daytime
It is dynamic, effectively prevent, mitigate and treat the complication caused by postprandial hyperglycemia.Zoopery proves, tea stalk of the present invention/
Tea stem extraction can inhibit the activity of intestine in rats alpha-glucosidase and amylase, reduce food source soup compound
It decomposes, reduces absorption of the enteron aisle to sugar, reduce the blood glucose level of sucrose feeding rat, and then reach reduction postprandial blood sugar and improvement
The effect of sugar tolerance.
Technical solution of the present invention second is that the above-mentioned preparation method for the hypoglycemic mixture containing plant component, including with
Lower three steps：S110 will trim tea stalk/tea stem mechanical crushing that tea tree obtains and be less than 0.85mm's (20 mesh) at average grain diameter
Powder, to obtain the tea stalk/tea stem micro mist；The tea stalk/tea stem the micro mist obtained in S120, step S110 adds with described
Agent is added to mix；S130 is prepared into scheduled dosage form by mixture is obtained in step S120.The dosage form is granule, tablet, glue
The clinical applications dosage form such as wafer.
The three of technical solution of the present invention are the above-mentioned preparation methods for the hypoglycemic mixture containing plant component, including with
Lower three steps：S210 will trim tea stalk/tea stem mechanical crushing of tea tree acquisition into powder；S220 obtains step S210
Raw material powder is mixed with solvent, and the solvent is water, ethyl alcohol or hydrous ethanol, and the weight ratio of the raw material powder and solvent exists
1: (10~20) then obtain the tea stalk/tea stem extraction by heating extraction, Microwave Extraction or ultrasonic extraction；S230, step
The tea stalk/tea stem extraction that rapid S220 is obtained is mixed with the additive, is then prepared into scheduled dosage form.
Further, step S220 include following three step by step：S221, the raw material powder that step S210 is obtained are mixed with water
It closes, first-time filtrate and a filter residue is obtained by filtration after heating extraction；S222 mixes a filter residue with water again, heating
Secondary filtrate is obtained by filtration after second of extraction；S223 merges the first-time filtrate and the secondary filtrate, is concentrated to give described
Tea stalk/tea stem extraction.
Provided by the present invention for the two above preparation method of the hypoglycemic mixture containing plant component, one is first making
Standby average grain diameter is less than tea stalk/tea stem micro mist of 0.85mm, then is mixed with additive, is then prepared into scheduled dosage form；Secondly
It is that solvent is first made using water, ethyl alcohol or hydrous ethanol, prepares tea stalk/tea stem extraction, then mix with additive, be then prepared into
Scheduled dosage form.The form of micro mist or solvent extractable matter using grain size less than 0.85mm convenient for digesting and assimilating, and prepares work
Skill is simple, energy consumption is low, pollution-free.
The four of technical solution of the present invention be it is above-mentioned for hypoglycemic mixture containing plant component preparation Hyperglycemic health care
Application in product.
The five of technical solution of the present invention are above-mentioned to prepare hypoglycemic drug for hypoglycemic mixture containing plant component
In application.
The six of technical solution of the present invention are above-mentioned to prepare blood sugar reducing food for hypoglycemic mixture containing plant component
In application.
It is the constituent analysis of the tea stalk/tea stem extraction and tea extract of one embodiment below：
Experiment is analyzed using high performance liquid chromatography.DIONEX liquid phase analysis instrument is 3000 types of Ultimate, electronics
Balance is ten a ten thousandth types of Sartorius BP211D, and thermostatic drying chamber is Germany's Memmert types, and ultra-pure water instrument is Merck
Millipore companies, micromill are Hangzhou Xiong Huo Science and Technology Ltd.s, and acetonitrile is Fisher (chromatographically pure), and formic acid is wide
State chemical reagent factory (analysis is pure).Reference substance caffeine (Caffeine, Caff), theobromine (Theobromine, Tb), does not eat
Sub- catechin and gallate ((-)-Gallocatechin gallate, GCG), Epigallo-catechin gallate (EGCG)
((-)-Epigallocatechin gallate, EGCG) is purchased from Japanese Wako Pure Chemicals Co., Ltd.；Gallic acid (Gallic
Acid, GA), catechin ((+)-Catechin, C) is purchased from Sigma Co., USA；Nutgall catechin ((-)-
Gallocatechin, GC), epigallocatechin (Epigallocatechin, EGC), epicatechin (Epicatechin,
EC) it is purchased from Japanese Kurita Water Industries Ltd；L-Epicatechin gallate ((-)-Epicatechin-3-gallate, ECG)
Purchased from Shanghai Jing Chun biochemical technologies limited liability company.
Chromatographic condition, chromatographic column COSMOSIL 5C18-AR-II (4.6*250mm, 5 μm, Nacalai tesque.Inc.,
Japan), flow velocity 1ml/min, quantitative Detection wavelength are 231nm, and column temperature is 35 DEG C, sample size 20ul.Mobile phase A：H2O
(containing 0.1% formic acid)；Mobile phase B：CH3CN (contains 0.1% formic acid), and gradient elution program is shown in Table one.Test sample is through distilled water
It centrifuges, is analyzed through the laggard HPLC of 0.45 μm of water film filtering, each component content is shown in Table two in sample after dissolving.
It can be seen from table two in the extract of tea stalk/tea stem and tealeaves, the caffeine in tea extract
(Caffeine, Caff) content will be significantly larger than the extract of tea stalk/tea stem, may result in insomnia, excitement and palpitaition etc.
Adverse reaction；And the extract of tea stalk/tea stem is conducive to improve hyperglycemia rich in polyphenol active ingredients such as catechins, evades
The adverse reaction that caffeine is brought.
Table one, HPLC gradient elution program
Table two, alkaloid and polyphenol compound content (%) in tea stalk/tea stem and young tea leaves extract
| Extract component | Tealeaves | Tea stem | Tea stalk |
| GA | 0.15 | 0.17 | 0.20 |
| Tb | 0.26 | 0.05 | 0.03 |
| GC | 0.71 | 0.17 | 0.06 |
| EGC | 2.60 | 0.53 | - |
| C | 0.27 | 0.24 | 0.16 |
| Caff | 3.31 | 0.91 | 0.25 |
| EC | 0.85 | 0.58 | 0.17 |
| EGCG | 4.58 | 1.29 | - |
| GCG | 1.55 | 0.08 | - |
| ECG | 1.76 | 1.04 | 0.06 |
Note：Expression does not detect
Here is influence of the tea stalk/tea stem extraction to blood glucose after rat sucrose feeding.
Experimental animal is (dynamic purchased from Guangdong Province's medical experiment using the 7 week old SD rats of SPE grades of male, 200~240g of weight
Object center, credit number SCXK (Guangdong) 2013-0002).Experimental animal is raised in cleaning grade laminar-flow rack, environment temperature be 23 ±
2 DEG C, relative humidity is 75 ± 10%, and lighting hours is 12 hours/day (7:00~19:00).
Experimental animal is randomly divided into control group, tea stem extraction 50mg/kg groups, tea stem extraction 100mg/kg groups, tea stem
Extract 200mg/kg groups and tea stalk extract 50mg/kg groups, tea stalk extract 100mg/kg, tea stalk extract 200mg/kg
Group, every group 8, the fasting 12 hours before experiment starts, each administration group is through gastric infusion, and control group gavage is to isometric distillation
Water.After administration 30 minutes, gavage gives 2.5g/kg/5mL aqueous sucrose solutions, and 30 minutes, sugarcane before sucrose feeding respectively
15 after glucose load, 30,60 minutes different time points take blood through tail vein, measure the blood glucose level of its different time.Test number
Mean ± S.E.M is indicated according to this, and data processing is carried out using SPSS19.0 softwares, is examined using ANOVA and is carried out statistical analysis,
P < 0.05 are statistically significant.
Experimental result is as shown in Table 3, gives rat 2.5g/kg sucrose after 15 minutes, and blood glucose level reaches peak value, with
After be gradually reduced, tea stalk/tea stem extraction of various dose can significantly inhibit the rising (P < 0.01) of blood glucose value, and ethyl alcohol carries
Taking does not have notable difference between object and water extract.
Table three, determination of blood glucose level value (mmol/L) of the experimental rat after sucrose feeding
Note：* indicate that P < 0.05, * * indicate P < 0.01, there is significant difference compared with the control group.
Below be tea stalk/tea stem extraction to rat small intestine alpha-glucosidase (α-glucosidase) and alpha-amylase
(α-amylase) active influence.
Experimental animal is (dynamic purchased from Guangdong Province's medical experiment using the 7 week old SD rats of SPE grades of male, 200~240g of weight
Object center, credit number SCXK (Guangdong) 2013-0002).Experimental animal is raised in cleaning grade laminar-flow rack, environment temperature be 23 ±
2 DEG C, relative humidity is 75 ± 10%, and lighting hours is 12 hours/day (7:00~19:00).
Experimental animal is randomly divided into control group, tea stem extraction 50mg/kg groups, tea stem extraction 100mg/kg groups, tea stem
Extract 200mg/kg groups and tea stalk extract 50mg/kg groups, tea stalk extract 100mg/kg, tea stalk extract 200mg/kg
Group, every group 7.The fasting 12 hours before experiment starts, each administration group is through gastric infusion, and control group gavage is to isometric distillation
Water.After administration 30 minutes, experimental animal opens abdomen after yellow Jackets are anaesthetized, and takes out small intestine respectively three equal parts from upper end, note
For small intestine -1, small intestine -2 and small intestine -3, intestinal contents are taken out respectively, are placed on coverslip, and removed small intestinal mucosal and be placed in
On glass slide.The work of the small intestinal mucosal and alpha-glucosidase and alpha-amylase in intestinal contents of different parts is measured respectively
Property, while its protein content is measured, and the enzymatic activity in calculating and more same albumen quality.Experimental data with Mean ±
S.E.M is indicated, data processing is carried out using 19.0 softwares of SPSS, is examined using ANOVA and is carried out statistical analysis, p < 0.05 have
Statistical significance.
Experimental result is as shown in table four to table seven, the α-of tea stalk/tea stem extraction of various dose to small intestine different parts
The activity of glucuroide and alpha-amylase has different degrees of inhibiting effect, wherein to the alpha-glucosidase of small intestine epimere
Inhibiting effect is more apparent, stronger to the alpha-amylase inhibition of mid small bowel and hypomere.
Hyperglycemia after postprandial or load is diabetes and the important pathophysiological feature of prediabetes, while being also to make
At the major reason of diabetic complication, inhibit intestinal alpha-glucosidase enzyme and amylase activity, can slow down and reduce sugar
It absorbs, to reduce level of postprandial blood sugar.Tea stalk/tea stem extraction can inhibit the work of enteron aisle glucuroide and amylase
Property, be conducive to control postprandial blood sugar, reduce hemoglobin glycosylation.
Table four, the measurement (U/g protein) of alpha-glucosidase activity in the small intestinal mucosal of experimental animal
| Group | Dosage | Small intestine -1 | Small intestine -2 | Small intestine -3 |
| Control group | - | 234.6±48.5 | 248.3±54.2 | 210.5±39.6 |
| Tea stem extraction group | 50mg/kg | 124.7±32.1* | 136.2±51.2 | 168.3±23.7 |
| Tea stem extraction group | 100mg/kg | 108.2±13.5** | 126.3±38.2 | 159.6±34.8 |
| Tea stem extraction group | 200mg/kg | 71.2±18.5*** | 78.2±28.1** | 139.7±32.6 |
| Tea stalk extract group | 50mg/kg | 143.2±24.3* | 152.8±41.1 | 179.4±14.2 |
| Tea stalk extract group | 100mg/kg | 119.8±18.4** | 148.1±42.3 | 162.7±32.1 |
| Tea stalk extract group | 200mg/kg | 96.3±12.5** | 103.2±22.1** | 141.2±18.9 |
Note：* indicate that P < 0.05, * * indicate that P < 0.01, material * indicate P < 0.001, have statistics poor compared with the control group
It is different.
Table five, the measurement (U/g protein) of alpha-glucosidase activity in experimental animal small intestine tube chamber content
| Group | Dosage | Small intestine -1 | Small intestine -2 | Small intestine -3 |
| Control group | - | 231.8±24.9 | 258.7±39.4 | 372.1±36.2 |
| Tea stem extraction group | 50mg/kg | 153.7±16.5* | 246.8±31.5 | 319.7±33.2 |
| Tea stem extraction group | 100mg/kg | 123.6±18.2** | 187.3±33.4 | 242.8±27.9 |
| Tea stem extraction group | 200mg/kg | 116.8±0.017** | 153.9±26.3 | 184.6±20.3 |
| Tea stalk extract group | 50mg/kg | 164.2±27.2* | 255.3±29.6 | 330.4±18.5 |
| Tea stalk extract group | 100mg/kg | 134.6±20.6** | 218.2±40.1 | 268..4±30.7 |
| Tea stalk extract group | 200mg/kg | 122.2±19.3** | 206.5±22.8 | 256.9±31.6 |
Note：* indicate that P < 0.05, * * indicate P < 0.01, there is significant difference compared with the control group.
Table six, the measurement (U/g protein) of alpha-amylase activity in the small intestinal mucosal of experimental animal
| Group | Dosage | Small intestine -1 | Small intestine -2 | Small intestine -3 |
| Control group | - | 1886.3±263.2 | 1346.1±186.4 | 563.8±113.6 |
| Tea stem extraction group | 50mg/kg | 1536.4±326.7 | 821.7±94.2 | 466.8±58.2 |
| Tea stem extraction group | 100mg/kg | 1334.0±121.4 | 589.2±55.7* | 337.8±42.1* |
| Tea stem extraction group | 200mg/kg | 1263.6±136.7 | 463.8±43.7* | 328.1±73.8* |
| Tea stalk extract group | 50mg/kg | 1646.7±254.1 | 787.2±88.6 | 486.5±63.7 |
| Tea stalk extract group | 100mg/kg | 1516.6±98.6 | 611.7±104.5* | 421.8±52.7 |
| Tea stalk extract group | 200mg/kg | 1341.3±166.9 | 493.9±50.1* | 358.9±110.1* |
Note：* P < 0.05 are indicated, there is significant difference compared with the control group.
Table seven, the measurement (U/g protein) of alpha-amylase activity in experimental animal small intestine tube chamber content
| Group | Dosage | Small intestine -1 | Small intestine -2 | Small intestine -3 |
| Control group | - | 13886.4±2518.6 | 14623.7±3062.4 | 4221.5±526.7 |
| Tea stem extraction group | 50mg/kg | 12423.5±2201.5 | 4326.4±813.8** | 3213.4±929.2 |
| Tea stem extraction group | 100mg/kg | 8633.5±1269.2 | 2145.8±703.4** | 2628.3±824.3 |
| Tea stem extraction group | 200mg/kg | 4045.6±860.6* | 1880.5±691.5** | 1625.1±527.1.2** |
| Tea stalk extract group | 50mg/kg | 11373.8±2415.1 | 6211.4±593.8** | 3604.2±348.8 |
| Tea stalk extract group | 100mg/kg | 9125.7±991.8 | 4982.9±628.9** | 3383.4±779.8 |
| Tea stalk extract group | 200mg/kg | 3988.3±745.6* | 2780.6±483.7** | 2987.8±518.4 |
Note：* indicate that P < 0.05, * * indicate P < 0.01, there is significant difference compared with the control group.
Specific implementation mode
The specific implementation mode of the present invention is described further below.It should be noted that for these implementations
The explanation of mode is used to help understand the present invention, but does not constitute limitation of the invention.In addition, invention described below
Involved technical characteristic can be combined with each other as long as they do not conflict with each other in each embodiment.
Tea stem and tea stalk used in following embodiment are provided by Guizhou Pu'an Hong Xin tea processing factories, are the acquisition of winter pruning tea tree
Object, has cleaned and preliminary crushing.
Embodiment 1, the mixture containing tea stalk/tea stem micro mist for making blood sugar reducing food
Tea stem and tea stalk raw material are ground into the powder that average grain diameter is less than 0.85mm (20 mesh)；Every above-mentioned tea of 100 parts by weight
1 part of ascorbic acid, 0.2 part of dihydroxy acetic acid, 2 parts of PEARLITOL 25C, 20 parts of cornstarch, stearic acid are added in stalk/tea stem micro mist
3 parts of calcium, 100 parts of water, is dried after mixing；
It is that average grain diameter is less than the particle of 0.85mm to get the mixture that dried object, which crushes,.The mixture adds as bread
Add agent in use, 1~5g is added in every 100 grams of bread wheat flour speciallies.
Embodiment 2 makees the mixture containing tea stalk/tea stem micro mist of health-caring product capable of reducing blood sugar
Tea stem and tea stalk raw material are ground into the powder that average grain diameter is less than 0.85mm (20 mesh)；Every above-mentioned tea of 100 parts by weight
1 part of ascorbic acid, 0.2 part of dihydroxy acetic acid, 2 parts of PEARLITOL 25C, 10 parts of avicel cellulose, tristearin are added in stalk/tea stem micro mist
3 parts of sour calcium, 90 parts of water, are dried after mixing.
Dried object is tabletted or pill, or records as capsule.Tablet/pill/the capsule makees health-caring product capable of reducing blood sugar, temperature
Water delivery service is oral, takes 1~5g after the meal.
Embodiment 3, the preparation of tea stalk/tea stem extraction
Raw material is ground into coarse powder, 500g coarse powder is taken, sets in extractor, adds 20 times of amount water refluxing extractions, keeps boiling 8 small
When, filtering, filter residue adds 20 times of amount water refluxing extractions, and boiling 1 hour, filtering is kept to merge filtrate twice.Filtrate sets concentration
It is concentrated under reduced pressure into the liquid extract that relative density is 1.2 or so for 60 DEG C in tank, liquid extract, which takes out, is packed into pallet, so freeze-dried that carry
Take object about 50g.
Embodiment 4, the preparation of tea stalk/tea stem extraction
Raw material is ground into coarse powder, 500g coarse powder is taken, sets in extractor, 10 times of amount 50% ethanol water reflux is added to carry
It takes, boiling 2 hours, filtering, filter residue is kept to add 10 times of amount 50% alcohol reflux extractions, keep boiling 1 hour, filter, close
And filtrate twice.Filtrate sets in concentration tank and is concentrated under reduced pressure into the liquid extract that relative density is 1.0 or so for 60 DEG C, freeze-dried to obtain
Extract about 50g.
The extract, the tea extract prepared in aforementioned manners, be used for more than test analysis.
Embodiment 5 is used to prepare the mixture containing tea stalk/tea stem extraction of hypoglycemic drug
The above tea stalk/tea stem extraction is prepared into a variety of pharmaceutical preparations, adds conventional excipient, lubricant, anti-oxidant
The additives such as agent, preservative, colorant, sweetener；Wherein, preferred excipient has lactose, white sugar, PEARLITOL 25C, starch, knot
Crystalline cellulose etc.；Preferred lubricant has magnesium stearate, calcium stearate, talcum powder etc.；Preferred antioxidant have sulphite,
Ascorbic acid etc.；Preferred preservative has dihydroxy acetic acid, methaform etc..Tea stalk/tea stem extraction is mixed evenly with additive
Afterwards, granule, tablet, capsule or pill etc. is made.The mode of taking of said medicine preparation is postprandial oral, each taking agent
In amount tea stalk/tea stem extraction content be 0.2~0.6g.
Embodiments of the present invention are explained in detail above, but the present invention is not limited to described embodiments.It is right
For those skilled in the art, in the case where not departing from the principle of the invention and spirit, these embodiments are carried out more
Kind change, modification, replacement and modification, still fall in protection scope of the present invention.
Claims (10)
1. a kind of being used for hypoglycemic mixture containing plant component, characterized in that including tea stalk/tea stem micro mist or tea stalk/tea stem
Extract.
2. according to claim 1 be used for hypoglycemic mixture containing plant component, characterized in that further include anti-oxidant
Agent, preservative and sweetener, the antioxidant are the mixture of both sulphite or ascorbic acid or more, the anti-corrosion
Agent is the mixture of both dihydroxy acetic acid or methaform or more, the sweetener be sucrose or lactose or PEARLITOL 25C or with
The mixture of upper three.
3. according to claim 2 be used for hypoglycemic mixture containing plant component, characterized in that further include excipient with
Lubricant, the excipient are the mixtures of both starch or avicel cellulose or more, the lubricant be magnesium stearate or
The mixture of calcium stearate or talcum powder or more three.
4. according to claim 2 or 3 be used for hypoglycemic mixture containing plant component, characterized in that the dosage form of use
It is granule, tablet, capsule or pill.
5. a kind of preparing the method described in claim 1 for the hypoglycemic mixture containing plant component, characterized in that including
Three steps below：Tea stalk/tea stem mechanical crushing is less than the powder of 0.85mm by S110 at average grain diameter, described in obtaining
Tea stalk/tea stem micro mist；The tea stalk/tea stem the micro mist obtained in S120, step S110 is mixed with the additive；S130, will
Mixture is obtained in step S120 is prepared into scheduled dosage form.
6. a kind of preparing the method described in claim 1 for the hypoglycemic mixture containing plant component, characterized in that including
Three steps below：
S210 will trim tea stalk/tea stem mechanical crushing of tea tree acquisition into powder；
S220 mixes the step S210 raw material powders obtained with solvent, the solvent be water, ethyl alcohol or hydrous ethanol, it is described
Raw material powder and solvent weight ratio 1: (1~20), then pass through heating extraction, Microwave Extraction or ultrasonic extraction obtain institute
State tea stalk/tea stem extraction；
S230, the tea stalk/tea stem extraction that step S220 is obtained are mixed with the additive, are then prepared into scheduled dose
Type.
7. the preparation method according to claim 6 for the hypoglycemic mixture containing plant component, characterized in that step
S220 include following three step by step：S221, the powder that step S210 is obtained are mixed with water, are obtained by filtration after heating extraction primary
Filtrate and a filter residue；S222 remixes a filter residue with water, and secondary filter is obtained by filtration after second of extraction of heating
Liquid；S223 merges the first-time filtrate and secondary filtrate, is concentrated to give the tea stalk/tea stem extraction.
8. according to claim 1 be used for hypoglycemic mixture containing plant component answering in preparing health-caring product capable of reducing blood sugar
With.
9. according to claim 1 be used for hypoglycemic mixture containing plant component answering in preparing hypoglycemic drug
With.
10. according to claim 1 be used for hypoglycemic mixture containing plant component answering in preparing blood sugar reducing food
With.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810912913.9A CN108771718A (en) | 2018-08-09 | 2018-08-09 | For hypoglycemic mixture containing plant component and the preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810912913.9A CN108771718A (en) | 2018-08-09 | 2018-08-09 | For hypoglycemic mixture containing plant component and the preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108771718A true CN108771718A (en) | 2018-11-09 |
Family
ID=64028681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810912913.9A Pending CN108771718A (en) | 2018-08-09 | 2018-08-09 | For hypoglycemic mixture containing plant component and the preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108771718A (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1465359A (en) * | 2002-06-27 | 2004-01-07 | 中国科学院上海药物研究所 | Tea and Chinese wolfberry fruit extracts composition and use thereof |
| CN1562279A (en) * | 2004-04-01 | 2005-01-12 | 暨南大学 | Extract of cocoa tea in application for preparing medication and foodstuff of preventing and improving diabetes and clinical symptom |
| JP2007008883A (en) * | 2005-06-30 | 2007-01-18 | Suntory Ltd | Composition having blood glucose level-lowering action |
| CN101990965A (en) * | 2010-09-26 | 2011-03-30 | 华侨大学 | Method for preparing dietary fiber micropowder by tea stem and tea dust enzyme method |
| CN102526348A (en) * | 2012-03-27 | 2012-07-04 | 上海中药创新研究中心 | Medicine composition for regulating blood sugar level, preparation method thereof and application |
| CN102771593A (en) * | 2011-05-13 | 2012-11-14 | 贵州省生物研究所 | Ampelopsis grossedentata preparation for reducing blood sugar, blood lipid and blood pressure and its preparation method |
| CN104172179A (en) * | 2014-07-03 | 2014-12-03 | 王健 | Extraction method of tea polyphenol |
| CN105920077A (en) * | 2016-06-15 | 2016-09-07 | 云南中医学院 | Preparation method of Herba Sambuci Adnatae extract and application thereof in rheumatoid arthritis |
-
2018
- 2018-08-09 CN CN201810912913.9A patent/CN108771718A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1465359A (en) * | 2002-06-27 | 2004-01-07 | 中国科学院上海药物研究所 | Tea and Chinese wolfberry fruit extracts composition and use thereof |
| CN1562279A (en) * | 2004-04-01 | 2005-01-12 | 暨南大学 | Extract of cocoa tea in application for preparing medication and foodstuff of preventing and improving diabetes and clinical symptom |
| JP2007008883A (en) * | 2005-06-30 | 2007-01-18 | Suntory Ltd | Composition having blood glucose level-lowering action |
| CN101990965A (en) * | 2010-09-26 | 2011-03-30 | 华侨大学 | Method for preparing dietary fiber micropowder by tea stem and tea dust enzyme method |
| CN102771593A (en) * | 2011-05-13 | 2012-11-14 | 贵州省生物研究所 | Ampelopsis grossedentata preparation for reducing blood sugar, blood lipid and blood pressure and its preparation method |
| CN102526348A (en) * | 2012-03-27 | 2012-07-04 | 上海中药创新研究中心 | Medicine composition for regulating blood sugar level, preparation method thereof and application |
| CN104172179A (en) * | 2014-07-03 | 2014-12-03 | 王健 | Extraction method of tea polyphenol |
| CN105920077A (en) * | 2016-06-15 | 2016-09-07 | 云南中医学院 | Preparation method of Herba Sambuci Adnatae extract and application thereof in rheumatoid arthritis |
Non-Patent Citations (1)
| Title |
|---|
| 尚进 等: "响应面法优化铁观音茶梗中茶多糖提取工艺", 《基因组学与应用生物学》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Effect of steeping temperature on antioxidant and inhibitory activities of green tea extracts against α-amylase, α-glucosidase and intestinal glucose uptake | |
| CN100998650A (en) | Use of cinnamonum cassia for treating diabetes, its products and preparing method | |
| CN101961060A (en) | Pu'er tea extract and preparation method and application | |
| CN104042679A (en) | Hypoglycemic product containing cyclocarya paliurus | |
| CN101548999A (en) | Preparation method and anti-obesic application of ginsenoside | |
| CN101181446A (en) | Application of sitsang scindapsus aureus flower as well as extract thereof in the preparation of diabetes medicament | |
| CN101474313B (en) | Application of theabrownin in pharmacy | |
| Zhang et al. | Serviceberry [Amelanchier alnifolia (Nutt.) Nutt. ex. M. Roem (Rosaceae)] leaf extract inhibits mammalian α-glucosidase activity and suppresses postprandial glycemic response in a mouse model of diet-induced obesity and hyperglycemia | |
| Selfayan et al. | Inhibitory effect of Capparis spinosa extract on pancreatic alpha-amylase activity | |
| KR101616811B1 (en) | Composition for treating diabete and diabete-induced complication containing an extract from Agrimonia pilosa | |
| Hussain et al. | Comparative in vitro analysis of anti-diabetic activity of Indo-Pak black cardamom (Amomum subulatum Roxb.) and Chinese black cardamom (Amomum tsao-ko Crevost et Lemaire) | |
| CN103719864A (en) | Blood glucose-reducing natto combined capsule and preparation method thereof | |
| Manzanilla Valdez et al. | Antidiabetic and hypotensive effect of Cnidoscolus aconitifolius (Mill) IM Johnst leaves extracts | |
| CN114271489B (en) | Anti-saccharification health-care food composition | |
| KR101426921B1 (en) | Composition comprising the porphyrinic compounds such as pheophorbide of Capsosiphon fulvescens for preventing or treating diabetes and diabetes complication, and antioxidant | |
| CN107778340A (en) | (20S, 24R) 20,24 epoxy dammarane 3 β, 12 β, 25 triols and its application | |
| CN102217755B (en) | Production method of Kusamaki seed extract and product | |
| CN108771718A (en) | For hypoglycemic mixture containing plant component and the preparation method and application thereof | |
| KR101050003B1 (en) | Composition for inhibiting obesity, containing the extract as an active ingredient | |
| KR100473530B1 (en) | Composition containing an extract of sopungsungi-won crude drug complex for preventing and treating diabetes mellitus | |
| JP2007520548A (en) | Composition for prevention and treatment of diabetic complications | |
| CN101884767B (en) | Plant extract composite for preventing diabetes complication and senium and preparation method thereof | |
| KR100473531B1 (en) | Composition containing an extract of truncated sopungsungi-won crude drug complex for preventing and treating diabetes | |
| CN101646428A (en) | Be used for the treatment of or prevent diabetes comprise medical composition and its use from the alkannin derivant of Radix Arnebiae (Radix Lithospermi) | |
| CN101433534B (en) | Use of resveratrol dimer for preparing medicament for reducing blood sugar |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181109 |